Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
BackgroundQuantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/85c1b16bc6ce4583a9afe49ce90637c0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:85c1b16bc6ce4583a9afe49ce90637c0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:85c1b16bc6ce4583a9afe49ce90637c02021-12-01T18:19:04ZEffect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial1664-239210.3389/fendo.2021.790405https://doaj.org/article/85c1b16bc6ce4583a9afe49ce90637c02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.790405/fullhttps://doaj.org/toc/1664-2392BackgroundQuantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron emission tomography (PET) with a radioactive tracer targeting activated macrophages in the vessel-wall.MethodsThirty randomly selected participants with type 2 diabetes from the placebo-controlled trial LIRAFLAME were enrolled in this sub-study. Participants were, prior to enrollment in this sub-study, randomized to either treatment with daily liraglutide (n=15) or placebo (n=15). Both groups underwent a combined [64Cu]Cu-DOTATATE positron emission tomography and computed tomography scan of the heart at baseline and after 26 weeks of treatment. Coronary artery uptake of [64Cu]Cu-DOTATATE were measured as maximum standardized uptake values (SUVmax); and means of the maximum values (mSUVmax), both values were calculated at the level of each participant and each individual coronary-segment.ResultsSUVmax and mSUVmax values decreased significantly in the liraglutide group both at the participant level (SUVmax: p=0.013; mSUVmax: p=0.004) and at the coronary-segment level (SUVmax: p=0.001; mSUVmax: p<0.0001). No change was observed in the placebo group neither at the participant level (SUVmax: p=0.69; mSUVmax: p=0.67) or at the coronary-segment level (SUVmax: p=0.49; mSUVmax: p=0.30). When comparing the mean change in uptake values between the two groups at both the participant level (SUVmax: p=0.076; mSUVmax: p=0.077) and the coronary segment level (SUVmax: p=0.13; mSUVmax: p=0.11) a borderline significant difference was observed. Baseline SUVmax [64Cu]Cu-DOTATATE uptake values showed a weak positive correlation with the inflammatory biomarker high-sensitivity c-reactive protein (τ =0.26, p=0.045).ConclusionLiraglutide treatment for 26-weeks caused a significant reduction in [64Cu]Cu-DOTATATE uptake in the coronary arteries whereas this was not seen in the placebo treated group. In addition, [64Cu]Cu-DOTATATE PET/CT as a marker of coronary inflammation correlated with the systemic inflammation marker hs-CRP.Jacob K. JensenEmilie H. ZobelEmilie H. ZobelBernt J. von ScholtenBernt J. von ScholtenViktor Rotbain CurovicTine W. HansenPeter RossingAndreas KjaerRasmus S. RipaFrontiers Media S.A.articleinflammationcoronary arteriesPETtype 2 diabetesmolecular imagingatherosclerosisDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
inflammation coronary arteries PET type 2 diabetes molecular imaging atherosclerosis Diseases of the endocrine glands. Clinical endocrinology RC648-665 |
| spellingShingle |
inflammation coronary arteries PET type 2 diabetes molecular imaging atherosclerosis Diseases of the endocrine glands. Clinical endocrinology RC648-665 Jacob K. Jensen Emilie H. Zobel Emilie H. Zobel Bernt J. von Scholten Bernt J. von Scholten Viktor Rotbain Curovic Tine W. Hansen Peter Rossing Andreas Kjaer Rasmus S. Ripa Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial |
| description |
BackgroundQuantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron emission tomography (PET) with a radioactive tracer targeting activated macrophages in the vessel-wall.MethodsThirty randomly selected participants with type 2 diabetes from the placebo-controlled trial LIRAFLAME were enrolled in this sub-study. Participants were, prior to enrollment in this sub-study, randomized to either treatment with daily liraglutide (n=15) or placebo (n=15). Both groups underwent a combined [64Cu]Cu-DOTATATE positron emission tomography and computed tomography scan of the heart at baseline and after 26 weeks of treatment. Coronary artery uptake of [64Cu]Cu-DOTATATE were measured as maximum standardized uptake values (SUVmax); and means of the maximum values (mSUVmax), both values were calculated at the level of each participant and each individual coronary-segment.ResultsSUVmax and mSUVmax values decreased significantly in the liraglutide group both at the participant level (SUVmax: p=0.013; mSUVmax: p=0.004) and at the coronary-segment level (SUVmax: p=0.001; mSUVmax: p<0.0001). No change was observed in the placebo group neither at the participant level (SUVmax: p=0.69; mSUVmax: p=0.67) or at the coronary-segment level (SUVmax: p=0.49; mSUVmax: p=0.30). When comparing the mean change in uptake values between the two groups at both the participant level (SUVmax: p=0.076; mSUVmax: p=0.077) and the coronary segment level (SUVmax: p=0.13; mSUVmax: p=0.11) a borderline significant difference was observed. Baseline SUVmax [64Cu]Cu-DOTATATE uptake values showed a weak positive correlation with the inflammatory biomarker high-sensitivity c-reactive protein (τ =0.26, p=0.045).ConclusionLiraglutide treatment for 26-weeks caused a significant reduction in [64Cu]Cu-DOTATATE uptake in the coronary arteries whereas this was not seen in the placebo treated group. In addition, [64Cu]Cu-DOTATATE PET/CT as a marker of coronary inflammation correlated with the systemic inflammation marker hs-CRP. |
| format |
article |
| author |
Jacob K. Jensen Emilie H. Zobel Emilie H. Zobel Bernt J. von Scholten Bernt J. von Scholten Viktor Rotbain Curovic Tine W. Hansen Peter Rossing Andreas Kjaer Rasmus S. Ripa |
| author_facet |
Jacob K. Jensen Emilie H. Zobel Emilie H. Zobel Bernt J. von Scholten Bernt J. von Scholten Viktor Rotbain Curovic Tine W. Hansen Peter Rossing Andreas Kjaer Rasmus S. Ripa |
| author_sort |
Jacob K. Jensen |
| title |
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial |
| title_short |
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial |
| title_full |
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial |
| title_fullStr |
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial |
| title_full_unstemmed |
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial |
| title_sort |
effect of 26 weeks of liraglutide treatment on coronary artery inflammation in type 2 diabetes quantified by [64cu]cu-dotatate pet/ct: results from the liraflame trial |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/85c1b16bc6ce4583a9afe49ce90637c0 |
| work_keys_str_mv |
AT jacobkjensen effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT emiliehzobel effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT emiliehzobel effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT berntjvonscholten effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT berntjvonscholten effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT viktorrotbaincurovic effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT tinewhansen effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT peterrossing effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT andreaskjaer effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial AT rasmussripa effectof26weeksofliraglutidetreatmentoncoronaryarteryinflammationintype2diabetesquantifiedby64cucudotatatepetctresultsfromtheliraflametrial |
| _version_ |
1718404703429066752 |